From 144281dd3a2faa16b001f7820e5acae139526374 Mon Sep 17 00:00:00 2001 From: borja Date: Tue, 4 Feb 2025 13:29:11 +0100 Subject: [PATCH] Auto saved by Logseq --- journals/2025_02_04.md | 4 +++- 1 file changed, 3 insertions(+), 1 deletion(-) diff --git a/journals/2025_02_04.md b/journals/2025_02_04.md index ff491064..f22d128f 100644 --- a/journals/2025_02_04.md +++ b/journals/2025_02_04.md @@ -6,7 +6,9 @@ En 2017, Mundo Sano se alió con EDCTP para financiar conjuntamente ensayos clínicos de herramientas innovadoras destinadas a enfermedades infecciosas desatendidas. De esta iniciativa surgieron los proyectos STOP 1 y 2, que llevaron a cabo el ensayo clínico (fase 2/3) que ha sustentado el dossier enviado a EMA. También son la base del proyecto STOP2030, del que forma parte Mundo Sano y que busca generar nuevas evidencias sobre seguridad en grandes poblaciones, coste eficiencia y aceptabilidad. - Inglés - - Last Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive scientific opinion for the fixed-dose combination of albendazole and ivermectin for the treatment of soil-transmitted helminths (STH) and lymphatic filariasis (LF). This marks a significant milestone for a public-private collaboration between more than a dozen partners for over a decade, with + - The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive scientific opinion for the fixed-dose combination of albendazole and ivermectin for the treatment of soil-transmitted helminths (STH) and lymphatic filariasis (LF). This marks a significant milestone for this pharmacological tool and brings it closer to its mass adoption in endemic countries. + - +- - - # #Tareas - TODO AFINAR el mensaje para enviar a [[EDCTP]]